Thrombolytic treatment for acute myocardial infarction increases the risk of subsequent reocclusion of the infarct related artery. The efficacy and safety of repeat thrombolytic treatment was assessed in 31 patients treated with streptokinase (n = 13) or tissue plasminogen activator (n = 18) a median of five days (1-716) after the first infusion. The indication for readministration was prolonge...

Pulmonary edema is rare in patients with pulmonary embolism and to our knowledge has not been described in association with thrombolytic therapy. We describe a patient with massive pulmonary embolism in whom the adult respiratory distress syndrome (ARDS) developed shortly after a course of streptokinase therapy. The possible association between streptokinase therapy or pulmonary embolism and AR...

OBJECTIVE To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction. DESIGN Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgG1 were assessed by an enzyme linked immunosorbent assay. SETTING Coronary...

Pump failure, ranging from ventricular dysfunction to acute cardiogenic shock, is now the leading cause of cardiac death. Efforts at temporary mechanical or pharmacologic support of the heart have been largely unsuccessful so that attention is now directed toward prevention of ventricular failure and limitation of myocardial infarct size or even outright prevention of infarction itself. In part...

Streptokinase is an extracellular protein secreted by various strains of streptococci and is used clinically as an intravenous thrombolytic agent for the treatment of acute myocardial infarction. It is well established that the fibrinolytic activity of streptokinase originates in its ability to activate plasminogen. The present investigation was carried out to determine the extent of streptokin...

The activity of alpha-hydroxybutyrate dehydrogenase, creatine kinase, creatine kinase MB and aspartate aminotransferase was measured on serial plasma samples from patients with acute myocardial infarction. The study was part of a multicentre randomised trial of the effect of thrombolytic treatment in the acute phase of acute myocardial infarction. The applicability and comparability of enzyme t...

The term " thrombolytic therapy " refers to the attempted removal of preformed intravascular fibrin occlusions using fibrinolytic agents. Several substances have been described as inducing a fibrinolytic state in the peripheral blood ; however, for only a few of these (namely, the plasminogen activators streptokinase and urokinase) was it proved beyond reasonable doubt that administration resul...

background: myocardial infarction (mi) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following mi in most countries including iran. our previous study showed that, the prevalence of high antibody titers a...

determination of streptokinase activity is usually accomplished through two assay methods: a) clot lysis, b) chromogenic substrate assay. in this study the biological activity of two streptokinase products, namely streptase®, which is a native product and heberkinasa®, which is a recombinant product, was determined against the third international reference standard using the two forementioned a...

OBJECTIVE To investigate the effect of heparin and thrombolytic agents on superoxide generation by human neutrophils, as inhibition of superoxide production may have a role in reducing ischaemia and reperfusion injury. METHODS Neutrophil superoxide production stimulated by phorbol myristate acetate (PMA), opsonised zymosan, or formyl methionyl leucyl phenylalanine (FMLP) was measured as the s...